TP53 and B-cell chronic lymphocytic leukemia: Venetoclax is indicated as single agent for R/R CLL patients who failed chemoimmunotherapy and one BCR inhibitor, and in patients with TP53 deletion/mutation who failed or are unsuitable for BCR inhibitors.